Neoadjuvant sacituzumab govitecan plus pembrolizumab achieved a 39% clinical complete response requiring concordant radiographic negativity and pathologic clearance ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

The post If Your Period Is Quietly Running Your Life, It’s Time to Pay Attention appeared first on Katie Couric Media.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...